Brilliant Violet 605™ anti-mouse CD3 Antibod
- 产品名称：
- Brilliant Violet 605™ anti-mouse CD3 Antibod
- 产品类别：
- 抗体
- 产品编号：
- 100237
- 产品应用：
- 100237
- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- γδTCR-positive T-T hybridoma D1
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605? under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 605? excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605? is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet?.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. - Excitation Laser
- Violet Laser (405 nm)
- Application Notes
Additional reported application (for relevant formats) include: spatial biology (IBEX)1,2.
- Application References
(PubMed link indicates BioLegend citation) -
- Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
- Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
- Product Citations
-
- Yu‐Han Chang et al. 2017. Immunity. 47(5):943-958 . PubMed
- Chandran S, et al. 2020. Front Immunol. 11:787. PubMed
- Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed
- Pettini E, et al. 2021. Vaccines (Basel). 9:. PubMed
- Rosenkranz SC, et al. 2021. eLife. 10:00. PubMed
- Thelin MA, et al. 2017. Diabetes. 66:2220. PubMed
- Mancini M, et al. 2019. J Immunol. 202:1479. PubMed
- Tata A, et al. 2021. Oncoimmunology. 10:1933808. PubMed
- Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
- Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
- Pokrovskii M, et al. 2019. Immunity. 51:185. PubMed
- Wabitsch S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1166. PubMed
- Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
- Piper CJM, et al. 2020. Cell Reports. 29(7):1878-1892.e7.. PubMed
- Stein RR, et al. 2018. Elife. 7:e30916. PubMed
- Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
- B?ttcher JP, et al. 2018. Cell. 172:1022. PubMed
- Israelow B, et al. 2021. Sci Immunol. 6:eabl4509. PubMed
- Yu X, et al. 2021. Nature. 594:560. PubMed
- Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed
- An J, et al. 2022. iScience. 25:103570. PubMed
- Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
- McBride KM, et al. 2019. Front Oncol. 9:517. PubMed
- Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
- Schuldt N, et al. 2015. PLoS One. 10: 0145762. PubMed
- Camell CD, et al. 2020. Cell Metabolism. 30(6):1024-1039.e6.. PubMed
- Zhang W, et al. 2022. Nat Methods. 19:759. PubMed
- Breznik JA, et al. 2021. The Journal of Physiology. 599(8):2169-2195. PubMed
- Lee SC et al. 2018. Cancer cell. 34(2):225-241 . PubMed
- Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
- Rosser EC, et al. 2020. Cell Metabolism. 31(4):837-851. PubMed
- Ferrer-Font L, et al. 2020. Elife. 9:. PubMed
- Voigt A, et al. 2015. Biol Open. 10.1242/bio.013771. PubMed
- Satoh–Takayama N, et al. 2020. Immunity. 52(4):635-649. PubMed
- Ryu S, et al. 2021. eLife. 0.416666666666667. PubMed
- Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
- Alam IS, et al. 2020. Cancer Res. 80:4780. PubMed
- Lee CH, et al. 2018. Elife. 7:e32532. PubMed
- Ito Y, et al. 2021. Cell Reports. 35(4):109052. PubMed
- Denk F, et al. 2016. Cell Rep. 15: 1771-1781. PubMed
- Matei DE, et al. 2021. Med (N Y). 2:864. PubMed
- RRID
- AB_2562039 (BioLegend Cat. No. 100237)
- Structure
- Ig superfamily, CD3/TCR, 20 kD
- Distribution
-
Thymocytes (differentiation dependent), mature T cells, NK-T cells
- Function
- Antigen recognition, TCR signal transduction, T cell activation
- Ligand/Receptor
- Peptide antigen/MHC-complex
- Antigen References
-
1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.
- Gene ID
- 12502 View all products for this Gene ID
- UniProt
- View information about CD3 on UniProt.org
